

University of Colorado Cancer Center

Minisymposium

Structural Biology in Cancer Drug Design

March 21, 2008

Research Hensel Phelps Auditorium - West, UCD, Aurora CO

Register online by March 7: www.uchsc.edu/pharmacology/UCCCsymposium/

Session 1 9:00-10:30

9:00-9:40 John Kuriyan (UC Berkeley) *Allosteric Control Mechanism in the Activation of the EGF Receptor*

9:50-10:20 Kate Ferguson (UPenn) *Mechanisms of inhibition of ligand-induced EGFR dimerization by therapeutic antibodies*

Coffee break 10:30-11:00

Session 2 11:00-12:30

11:00-11:40 David Cowburn (New York Structural Biology Center) *Developing a dynamic structural view of protein tyrosine kinase regulation*

11:50-12:20 Tomi Sawyer (Aileron Therapeutics) *Exploring Chemical Space in Protein-Protein Interaction Drug Discovery*

Lunch 12:30-2:00 (provided by the Department of Pharmacology)

Session 3 2:00-3:30

2:00-2:40 Stephen Burley (SGX Pharmaceutical) *Discovery and development of selective, orally bioavailable tyrosine kinase inhibitors for targeted treatment of human cancers*

2:50-3:20 Brian Blagg (U Kansas) *Designing Old Drugs for New Targets, a Case Study with Novobiocin*

Coffee break 3:30-4:00

Session 4 4:00-5:30

4:00-4:40 Maurizio Pellecchia (Burnham) *NMR- and fragment-based approaches to drug design*

4:50-5:20 Rick Artis (Plexxikon) *Scaffold-based Drug Discovery in Oncology*

Sponsored by UC Cancer Center, Molecular Oncology Program, Cancer Cell Biology Program, Department of Pharmacology, Biomolecular Structure Program, Array BioPharma, Art Robbins, Bruker BioSpin, Bruker AXS, Spectra Stable Isotopes, Rigaku, Varian

Organizing Committee
Elan Eisenmesser
Tatiana Kutateladze
Rui Zhao